Home / Venlafaxine / Italy
IT ATC N06AX16 · updated 2 Nov 2026
Venlafaxine shortage in Italy
Is there a Venlafaxine shortage in Italy?
Yes. As of 2 Nov 2026, 12 Venlafaxine products are reported short in Italy, the first since 31 Jul 2023. The company estimate for the return is 28 Feb 2027. Main reason: manufacturing problem.
Also short in Canada, France, Spain, Ireland, Austria, Belgium, Czechia, New Zealand, Australia. All countries.
Affected products in Italy
| Country | Product | Company | Since | Expected back | Reason |
|---|---|---|---|---|---|
| IT | VENLAFAXINA ZENTIVA | ZENTIVA ITALIA S.R.L. | 31 Jul 2023 | not given | Manufacturing problem Problemi produttivi |
| IT | VENLAFAXINA ZENTIVA | ZENTIVA ITALIA S.R.L. | 20 Nov 2023 | not given | Manufacturing problem Problemi produttivi |
| IT | VENLAFAXINA MYLAN GENERICS | MYLAN S.P.A. | 15 Oct 2024 | not given | Manufacturing problem Problemi produttivi: forniture discontinue |
| IT | VENLAFAXINA MYLAN GENERICS | MYLAN S.P.A. | 15 Jul 2025 | not given | Manufacturing problem Problemi produttivi: forniture discontinue |
| IT | VENLAFAXINA ZENTIVA | ZENTIVA ITALIA S.R.L. | 31 Jul 2025 | not given | Increased demand Elevata richiesta |
| IT | VENLAFAXINA ZENTIVA | ZENTIVA ITALIA S.R.L. | 13 Aug 2025 | not given | Increased demand Elevata richiesta |
| IT | VENLAFAXINA ZENTIVA | ZENTIVA ITALIA S.R.L. | 31 Jan 2026 | not given | Manufacturing problem Problemi produttivi |
| IT | VENLAFAXINA EG STADA ITALIA | EG S.P.A. | 2 Sep 2026 | not given | Increased demand Elevata richiesta |
| IT | EFEXOR | VIATRIS PHARMA S.R.L. | 14 Sep 2026 | not given | Manufacturing problem Problemi produttivi |
| IT | VENLAFAXINA MYLAN GENERICS | MYLAN S.P.A. | 23 Sep 2026 | not given | Manufacturing problem Problemi produttivi |
| IT | VENLAFAXINA TEVA anticipated | TEVA B.V. | 9 Nov 2026 | 28 Feb 2027 | Increased demand Elevata richiesta/problemi produttivi |
| IT | VENLAFAXINA EG STADA ITALIA anticipated | EG S.P.A. | 24 Nov 2026 | not given | Manufacturing problem Problemi produttivi |
Source
AIFA (Italian Medicines Agency), licensed CC-BY 4.0. Official list. All shortages reported by marketing-authorisation holders, including medicines being withdrawn.